Skip to main content

Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Jubilant Biosys and Orion Corporation Announces Unique Collaborative Discovery Program in Pain Management Area

    (Business Wire India; 13th May, 2014); Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, and Orion Corporation (Orion), the largest pharmaceutical company in Finland, today announced a path breaking drug discovery collaboration to discover small molecule inhibitors in neuroscience therapeutic area. The research deal is aimed at developing drug that can benefit large population of people with unmet needs in the pain management area.

  • First time in India Continuing Pharmaceutical Education (CPE) to be held in Dombivli

    (12th May, 2014); InClinition, a Pharmaceutical and clinical research service providing organization situated in Dombivli, Dist. Thane has announced Continuing Pharmaceutical Education (CPE) discussion forum lecture series. This will be seminar cum networking session for industry and academic professionals.

  • New Study Suggests Desmopressin Melt Improves Sleep Patterns and Psychological Functioning of Bedwetting Children

    (Business Wire India; 12th May, 2014); New data has shown that treatment with melt-in-the-mouth desmopressin (MINIRIN® Melt)* improved sleep patterns and psychological functioning (including attention problems and memory) in children with nocturnal enuresis (bedwetting). The negative impact of bedwetting on children’s neuropsychological functioning (e.g. anxiety and social self-esteem problems) was also shown. The data from a study by researchers at the University Hospital Ghent, Belgium was presented at the 25th annual congress of the European Society for Paediatric Urology (ESPU) in Innsbruck, Austria.

  • CSIR-IHBT developed unique enzyme for creating global niche

    (11th May, 2014); CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur, has developed unique autoclavable Super Oxide Dismutase (SOD) enzyme, used in cosmetic, food and pharmaceutical industries for end applications, like developing anti-ageing creams, extending shelf life of fruits and vegetables and during cryo-surgery and preservation of organelles, respectively.

  • ACG's Pithampur Factory Awarded Gold Rating by LEED-India; First in Pharma Industry to Receive the Certification

    (PRNewswire; 6th May, 2014); ACG's continued commitment towards sustainability and efforts in building sustainable sites, reducing water and energy consumption, recycling building material and improving indoor environmental quality has now been recognized. Indian Green Building Council (IGBC) LEED®-India has awarded its prestigious Gold rating to ACG's new state-of-the-art capsule manufacturing plant in Pithampur, making it the first factory in Indian pharmaceutical industry to receive this rating.

  • Eczema may reduce risk of skin cancer

    (6th May, 2014);As per new findings by investigators from King’s College London, Eczema caused by defects in the skin could reduce the risk of developing skin cancer. The immune response generated by eczema could help prevent tumour formation by shedding potentially cancerous cells from the skin.

  • Researchers made Sperm Cells from Skin of infertile men

    (2nd May, 2014); Team of researchers from Montana State University showing that skin cells from infertile man can be used to create, primary germ cells - precursors of sperm. This research is providing ray of hope for future treatment of male infertility.

  • ElectroCore: Two separate studies on the treatment of migraine headache with non invasive vagus nerve stimulation are being presented at the American Association of Neurology (AAN) meeting in Philadelphia

    (1st May, 2014); At the AAN meeting in Philadelphia, two separate studies showed that electroCore’s non invasive vagus nerve stimulation (nVNS) therapy was effective in helping patients with different types of migraine. The first poster presentation, on April 28th, found that two hours after treatment with electroCore’s nVNS therapy patients who had both chronic migraine and medication overuse headache were pain free in 33% of attacks while significant pain relief (mild or no pain) was noted in 50% of attacks. In the second poster presented on May1st it was found that 45 % of patients, with migraine without aura, were pain free within 30 minutes of just one dose of nVNS therapy.

  • Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference

    (30th Apr, 2014);Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of idiopathic pulmonary fibrosis (IPF), will be presented at the 2014 American Thoracic Society (ATS) International Conference taking place 16 – 21 May in San Diego. IPF is a rare, debilitating and fatal lung disease for which treatment options are limited.

  • DTAB concern about wide variation in the quality of Generic Drugs

    (28th Apr, 2014); In their last meeting, Drugs Technical Advisory Board (DTAB) raised the issue of wide variation in the quality of generic drugs manufactured in the country by small scale sector. The generic medicines of lower quality have not been found effective in patients.

Subscribe to Pharma News